IGC Pharma expands Phase 2 CALMA trial with Butler Hospital, focusing on IGC-AD1 therapy for agitation in Alzheimer's disease. Dr. Meghan Riddle from Brown University to lead the trial, aiming to enroll 146 participants in the U.S.